Interestingly, ER fusion-driven cell growth can be suppressed by CDK4/6 inhibition, suggesting that targeting kinases downstream of ER could be a strategy to treat patients with ER translocated BC tumors. The gene discussed is ESR1; the disease is breast cancer.